Ferreira AA, Leite IC, Bustamante-Teixeira MT, Corrêa CS, da Cruz DT, Rodrigues Dde O, et al. Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index. (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013;35:314–8.

Article  PubMed  PubMed Central  Google Scholar 

Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129–35.

Article  CAS  PubMed  Google Scholar 

De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14:931–8.

Article  PubMed  Google Scholar 

van Os SB, Troop NA, Sullivan KR, Hart DP. Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients. PLoS ONE. 2017;12: e0169880.

Article  PubMed  PubMed Central  Google Scholar 

KyngÄs HA, Kroll T, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health. 2000;26:379–88.

Article  PubMed  Google Scholar 

Coppola A, Franchini M, Castaman G, Santagostino E, Santoro C, Santoro RC, et al. Treatment regimens with bypassing agents in patients with hemophilia A and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE). Semin Thromb Hemost. 2018;44:551–60.

Article  CAS  PubMed  Google Scholar 

Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116:S10–7.

Article  PubMed  Google Scholar 

Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Med. 2012;18:1570–4.

Article  CAS  PubMed  Google Scholar 

Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE. 2013;8: e57479.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–18.

Article  CAS  PubMed  Google Scholar 

Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–22.

Article  CAS  PubMed  Google Scholar 

Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295–305.

Article  PubMed  Google Scholar 

Yang R, Wang S, Wang X, Sun J, Chuansumrit A, Zhou J, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost. 2022;6: e12670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levy-Mendelovich S, Brutman-Barazani T, Budnik I, Avishai E, Barg AA, Levy T, et al. Real-world data on bleeding patterns of hemophilia a patients treated with emicizumab. J Clin Med. 2021;10:4303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Escuriola EC, Sidonio RF Jr. Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE). Ther Adv Hematol. 2021;12:20406207211032452. https://doi.org/10.1177/20406207211032452.

Article  CAS  Google Scholar 

Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensivetreatment centre in the US. Haemophilia. 2021;27:90–9.

Article  PubMed  Google Scholar 

Noguchi-Sasaki M, Soeda T, Ueyama A, Muto A, Hirata M, Kitamura H, et al. Emicizumab, a bispecific antibody to factors IX/IXa and X/Xa, does not interfere with antithrombin or TFPI activity in vitro. TH Open. 2018;2:e96–103.

Article  PubMed  PubMed Central  Google Scholar 

Yada K, Nogami K, Shinozawa K, Kitazawa T, Hattori K, Amano K, et al. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V. Br J Haematol. 2018;183:257–66.

Article  CAS  PubMed  Google Scholar 

Ellery PER, Hilden I, Thyregod P, Martinez ND, Maroney SA, Gill JC, et al. Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and protein S in people with haemophilia. Haemophilia. 2019;25:1083–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Ghamdi MA, Huwait EA, Kumosani TA, Qari M, Moselhy SS, Kumosani AT. Serum proteins C and S levels as early biomarkers for kidney dysfunction in hemophilic patients. Afr Health Sci. 2018;18:681–8.

Article  PubMed  PubMed Central  Google Scholar 

Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood. 1996;88:1183–7.

Article  CAS  PubMed  Google Scholar 

Veer van’t C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor V (LEIDEN). Blood. 1997;90:3067–72.

Article  Google Scholar 

Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost. 2000;83:387–91.

Article  CAS  PubMed  Google Scholar 

Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res. 2010;125:119–23.

Article  CAS  PubMed  Google Scholar 

Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240–6.

Article  CAS  PubMed  Google Scholar 

Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haemat. 2004;26:215–23.

Article  CAS  Google Scholar 

Tokugawa T, Ishiguro A, Ohira K, Okamoto K, Sakai M, Suzuki T, et al. Guideline of hemostatic treatments for patients with haemophilia—about usage of emicizumab. J JSTH. 2020;31:93–104.

Google Scholar 

Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994;83:683–90.

Article  CAS  PubMed  Google Scholar 

Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? Thromb J. 2016;14(Suppl 1):25.

Article  PubMed  PubMed Central  Google Scholar 

Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147–56.

Article  CAS  PubMed  Google Scholar 

Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878–85.

Article  CAS  PubMed  Google Scholar 

Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249–53.

Article  CAS  PubMed  Google Scholar 

Ogiwara K, Nogami K, Matsumoto N, Noguchi-Sasaki M, Hirata M, Soeda T, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Int J Hematol. 2020;112:621–30.

Article  CAS  PubMed